Synopsis:
Glenmark Pharmaceuticals jumped sharply after it received a whopping $700 million (Rs 6,160 Crore) upfront payment from AbbVie as part of an exclusive global licensing deal.
The shares of this leading pharmaceutical company are in focus after the company received a key payment from AbbVie (listed on the NYSE stock exchange). In this article, we will dive more into the details.
With a market capitalization of Rs 59,396 crore, the shares of Glenmark Pharmaceuticals Ltd made a day high of Rs 2,112.95 per share, up by 3 percent from its previous day closing price of Rs 2,052.65 per share. Over the past five years, the stock has delivered an impressive return of 336 percent.
About the announcement
Glenmark Pharmaceuticals, through a stock exchange filing, announced that its fully owned subsidiary, Ichnos Glenmark Innovation (IGI), has landed a whopping $700 million (Rs 6,160 Crore) upfront payment from AbbVie as part of an exclusive global licensing deal.
This agreement gives AbbVie the worldwide rights to IGI’s leading investigational asset, ISB 2001, which is set to be developed and marketed in major regions like North America, Europe, Japan, and Greater China.
This deal is a huge win for Glenmark, as that substantial upfront payment will boost its financial standing, lower its debt, and provide extra resources for future research and development efforts.
Plus, teaming up with a global biopharma giant like AbbVie highlights the impressive potential and credibility of IGI’s innovative pipeline. This partnership is expected to speed up the development of ISB 2001 and could pave the way for more growth opportunities for Glenmark in the global pharmaceutical arena.
Also Read: Defence stock jumps 4% after receiving ₹10 Cr order from Department of Atomic Energy
Financial Highlights
The company reported a revenue of Rs 3,264 crore in Q1 FY26, up by just 0.62 percent from its Q1 FY25 revenue of Rs 3,244. Similarly, revenue grew slightly by 0.25 percent from Rs 3,256 crore in its previous quarter.
Regarding its profitability, the company reported a net profit of Rs 47 crore in Q1 FY26, down significantly by 86 percent from its Q1 FY25 net profit of Rs 340 crore. However, it grew by 1,075 percent from Rs 4 crore in its previous quarter.
The main reason behind the weak profitability was the hefty U.S. litigation settlements, which heavily weighed on the company’s earnings. While these were one-time, non-recurring charges, they overshadowed Glenmark’s core operational performance, masking the steady growth in its global pharmaceutical business and ongoing R&D initiatives.
The stock delivered an ROE and ROCE of 15.79 percent and 19.40 percent respectively, and is currently trading at a P/E of 44.56x as compared to its industry average of 33.45x.
Glenmark Pharmaceuticals is a worldwide player in the pharma industry, known for producing and selling generics, specialty medicines, and over-the-counter (OTC) products across India, North America, Europe, and beyond.
They offer a range of treatments for various health issues, including skin conditions, respiratory problems, cancer, heart disease, diabetes, and more, available in forms like injections, tablets, liquids, creams, and inhalers.
The company is also hard at work developing new medications, such as ISB 2001 for multiple myeloma and ISB 2301 for solid tumors, along with several other drugs currently in different testing phases. Additionally, they market products like the Ryaltris nasal spray, which helps with seasonal allergies.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
